Teva Pharmaceutical Industries

Traded on the St. Petersburg Stock Exchange
Teva Pharmaceutical Industries is an Israeli multinational pharmaceutical company. It specializes primarily in generic drugs, but other business interests include active pharmaceutical ingredients and, to a lesser extent, proprietary pharmaceuticals.
Teva Pharmaceutical Industries stock price chart
vol.
change
P/E adj.
Net profit (adj.)
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Teva Pharmaceutical Industries balance sheet

Report period2019 2020 2021 2022 2023 Q2 24
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Teva Pharmaceutical Industries cash flows

Report period2019 2020 2021 2022 2023 Q2 24 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
Adjusted Earnings
EBITDA
Adjusted EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS
Adjusted EPS

Teva Pharmaceutical Industries multipliers

Report period2019 2020 2021 2022 2023 Q2 24 TTM
P/E
P/E adj.
E/P
E adj./P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
Net Debt/EBITDA adj.
EV/EBITDA
EV/EBITDA adj.

Teva Pharmaceutical Industries profitability

Report period2019 2020 2021 2022 2023 Q2 24 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Teva Pharmaceutical Industries assets
Teva Pharmaceutical Industries cash flows
Teva Pharmaceutical Industries dividends
0%

Teva Pharmaceutical Industries dividend policy

The company pays dividends on a quarterly basis.

Teva Pharmaceutical Industries shares

TickerNameTypeNominal valueISINPrice
TEVA:USTeva Pharmaceutical Industries LimitedCommon share-US8816242098$17.11
Teva Pharmaceutical Industries news
03.05.2022
Teva Pharmaceutical Industries' GAAP loss for 3 months of 2022 was $952 million, against a profit of $84 million in the previous year. Revenues decreased by 8.1% to $3.661 billion from $3.982 billion the year before.
Source: {source} pictogram ir.tevapharm.com
Pictogram next
09.02.2022
Teva Pharmaceutical Industries' GAAP net income for 2021 was $0.456 billion, compared with a loss of $4.099 billion in the previous year. Revenues decreased by 4.7% to $15.878 billion from $16.659 billion the year before.
Source: {source} pictogram ir.tevapharm.com
Pictogram next
27.10.2021
Teva Pharmaceutical Industries' GAAP net profit for 9M 2021 amounted to $0.608 bln, against a loss of $4.261 bln in the previous year. Revenues fell 3.5% to $11.778 billion from $12.206 billion a year earlier.
Source: {source} pictogram ir.tevapharm.com
Pictogram next
28.07.2021
Teva Pharmaceutical Industries net profit according to GAAP for 6 months of 2021 amounted to $306 million, increasing 3.9 times compared to $78 million in the previous year. Revenues decreased 4.1% to $7.892 billion from $8.227 billion a year earlier.
Source: {source} pictogram ir.tevapharm.com
Pictogram next
All Teva Pharmaceutical Industries news
General information
Company nameTeva Pharmaceutical Industries
Tags#pharmacy
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals
Business address5 BAZEL ST P O B 3190 PETACH TIKVA L3 49131 9729267267
Mailing addressTEVA PHARMACEUTICAL INDUSTRIES LIMITED 5 BAZEL ST PO B 3190 PETACH TIKVA L3 49131
Websitewww.tevapharm.com
Information disclosurewww.sec.gov